Monocyte-suppressing effect of high-dose metformin in fenofibrate-treated patients with impaired glucose tolerance

Pharmacological Reports

Volumn 65, Issue 5, 2013, Pages 1311-1316

  Krysiak, Robert ^a   Gdula Dymek, Anna ^a   Okopieñ, Bogusaw ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Fibrates; Inflammatory cells; Low grade inflammation; Metformin; Prediabetes

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; FATTY ACID; FENOFIBRATE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DIARRHEA; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; FEMALE; GLUCOSE HOMEOSTASIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; MALE; MONOCYTE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VOMITING;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CYTOKINES; FEMALE; FENOFIBRATE; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; INFLAMMATION MEDIATORS; LIPIDS; MALE; METFORMIN; MIDDLE AGED; MONOCYTES; POLAND; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84894180189     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/s1734-1140(13)71489-0     Document Type: Article

References (16)

1. Hansson GK: Inflammatory mechanisms in atherosclerosis. J Thromb Haemost, 2009, 7, Suppl 1, 328-331.
2. Kher N,Marsh JD: Pathobiology of atherosclerosis -a brief review. Semin Thromb Hemost, 2004, 30, 665-672.
3. Krysiak R, Gdula-Dymek A, Bachowski R, Okopieñ B: Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes. Diabetes Care, 2010, 33, 2266-2270.
4. Krysiak R, Gdula-Dymek A, Okopieñ B: Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia. Am J Cardiol, 2011, 107, 1010-1018.
5. Krysiak R, Gdula-Dymek A, Okopieñ B: Hemostatic effects of bezafibrate and w-3 fatty acids in isolated hypertriglyceridemic patients. Pharmacol Rep, 2011, 63, 763-771.
6. Krysiak R, Handzlik G, Okopieñ B: Hemostatic effects of fenofibrate in patients with mixed dyslipidemia and impaired fasting glucose. Pharmacol Rep, 2010, 62, 1099-1107.
7. Okopieñ B, Krysiak R, Haberka M, Herman ZS: Effect of monthly atorvastatin and fenofibrate treatment on monocyte chemoattractant protein-1 release in patients with primary hypercholesterolemia. J Cardiovasc Pharmacol, 2005, 45, 314-320. (Pubitemid 40411286)
8. Okopieñ B, Krysiak R, Herman ZS: Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab, 2006, 91, 1770-1778.
9. Okopieñ B, Krysiak R, Kowalski J, Madej A, Belowski D, Zieliñski M, Herman ZS: Monocyte release of tumor necrosis factor-a and interleukin-1b in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates. J Cardiovasc Pharmacol, 2005, 46, 377-386. (Pubitemid 41262842)
10. Petersen JL, McGuire DK: Impaired glucose tolerance and impaired fasting glucose -a review of diagnosis, clinical implications and management. Diab Vasc Dis Res, 2005, 2, 9-15. (Pubitemid 40333199)
11. Pruski M, Krysiak R, Okopieñ B: Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. Diabetes Care, 2009, 32, 1421-1424.
12. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR et al.: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet, 2010, 375, 735-742.
13. Scarpello JH, Howlett HC: Metformin therapy and clinical uses. Diab Vasc Dis Res, 2008, 5, 157-167.
14. Tedgui A, Mallat Z: Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev, 2006, 86, 515-581.
15. Twigg SM, Kamp MC, Davis TM, Neylon EK, Flack JR; Australian Diabetes Society; Australian Diabetes Educators Association: Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust, 2007, 186, 461-465. (Pubitemid 46806823)
16. Wilson HM, Barker RN, Erwig LP: Macrophages: promising targets for the treatment of atherosclerosis. Curr Vasc Pharmacol, 2009, 7, 234-243.